Risk information should increase as benefit information increases
Rule
As a piece devotes more content to benefit claims, it should correspondingly devote more content to risk information.
Check
Compare the volume (word count, time, space) of benefit content to risk content; the piece does not need identical amounts of benefit and risk content. The test is whether risk content keeps pace with benefit content given how many risks the product actually has, so flag pieces where benefit content grows substantially without a comparable increase in risk content. Do not flag a piece for a product with a minimal number of risks when all of those risks are conveyed with prominence comparable to the benefit information, even if the piece has several more benefit claims than risk claims. Matching volume alone does not show compliance and mismatched volume alone does not show a violation; volume is one factor in the overall net-impression judgment.
Escalate when
When benefit content is extensive relative to a comparatively thin risk presentation, and the product does not fall within the minimal-risk, comparable-prominence carve-out.
Where this comes from
Section III.B.1, Quantity · page 13. The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.
…. B. CONSIDERATIONS OF CONTENT This section discusses how FDA evaluates the content of risk presentations in determining whether a promotional piece is accurate and non-misleading. 1. Quantity One content factor FDA considers is the amount or quantity of information conveyed by a promotional piece. For example, a 30-second broadcast ad is likely to present less information than a 60-second broadcast ad. As the amount of benefit information conveyed increases, the amount of risk information conveyed should similarly increase. The quantity of information presented can affect the net impression of the piece. The amount of information presented is one component that, together with choice of words, color, graphics, voiceover, and other aspects of the piece, can affect cognitive load, the mental effort required to understand the various components of information in the piece. If the benefit information is easily understo…
- Document
- FDA guidance: Presenting Risk Information in Prescription Drug and Medical Device Promotion (see document)
- Version
- as retrieved — the publisher does not version this document; the fingerprint below identifies the exact file
- Retrieved
- 2026-09-21 from www.fda.gov
- Fingerprint
- f5654ab082f6cd4408143f16…
FDA guidance describes the agency's current thinking. It is not binding law, and this rule is a recommendation, not an obligation.